NCT00144235

Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue

A 28 Day, Randomised, Double-blind, Placebo-controlled, Single-centre Trial to Evaluate the Efficacy and Safety of Pharmaton® PHL 00749 Film Coated Tablets (G115 40 mg, Multivitamin, Multimineral + Guarana 75 mg) 1/Day p.o. in Improving Mental Performance and to Decrease Fatigue in Healthy Male and Female Subjects in Regular Employment.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 412 (planned)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 20 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of Pharmaton? PHL 00749 in improving cognitive function and allevi ating mental and physical stress in healthy male and female subjects leading demanding lifestyles.

Detailed description

This is a double-blind, placebo-controlled, randomised, parallel group trial in healthy male and fem ale subjects in regular employment. The duration of dosing will be 28 '(+/- 1)' days and assessments w ill be made on two visits (visits 2 and 3) with a training on the CDR system at the screening visit. The subjects will receive one bottle with 35 tablets \[of either Ginseng G115 40 mg, multivitamin, mu ltimineral '+' Paullinia cupana extract PC102 75 mg (Guarana) or placebo\] from the pharmacy at the in vestigational site. The subjects should take the study drug from day 0 to day 28 '(+/- 1)' Subjects will be assigned to one of the two treatment groups randomly. The allocation ratio is 2:1.. Study Hypothesis: H0: No difference exists between the treatment and the placebo groups in terms o f baseline-adjusted change in Power of Attention after 28 days and averaged over 4 and 6 hour time point. H1: A difference exists between the treatment and the placebo groups in terms of baseline-adjusted change in Power of Attention after 28 days and averaged over 4 and 6 hour time point. The null and alternative hypotheses for the secondary endpoints are set up accor dingly. The statistical testing will be carried out at the 0.05 level of signifi cance. The test will be performed two-tailed. Comparison(s): The comparator is a matching placebo film-coated tablet without active ingredien ts.

Conditions

• Mental Competency
• Mental Fatigue

Interventions

Type	Name	Description
DRUG	Pharmaton PHL 00749
DRUG	Placebo

Timeline

• Start date: 2005-03-01
• Primary completion: 2005-07-01
• Completion: 2005-07-01
• First posted: 2005-09-05
• Last updated: 2013-10-31

Locations

1 site across 1 country: United Kingdom